YD Bio Limited is set to begin trading on the Nasdaq Global Market on August 29, 2025, under the ticker symbols “YDES” and “YDESW” following a successful business combination with Breeze Holdings Acquisition Corp. The company closed a PIPE offering, raising over $11.5 million to fund future operations. Led by Chairman Dr. Ethan Shen, YD Bio focuses on DNA methylation-based cancer detection technology and ophthalmologic innovations, including stem cell and exosome therapies for ocular diseases. The move to the public markets will allow YD Bio to accelerate innovation, scale production, and drive the development of groundbreaking healthcare solutions.

Read more at GlobeNewswire: YD Bio Limited Announces Closing of Business Combination